The Israeli company said in a release the treatment met its primary endpoint and all secondary endpoints in the treatment of patients with deep partial thickness and full thickness thermal burns. MediWound plans to submit a license application to the Food and Drug Administration in the second half of 2019.
Shares of MediWound climbed $0.47, or 11%, to $4.85 in Tuesday’s premarket trading.
“We are thrilled to announce these robust positive results across all endpoints,” Gal Cohen, president and CEO of
Cohen added that the results corroborated positive European Union Phase 3 findings.
The primary endpoint was complete removal of eschar, the dead tissue found in a wound, according to MediWound. Secondary endpoints included reduction in the need for surgical eschar removal, earlier eschar removal and blood loss.
The study involves 44 burn centers, according to MediWound.
Contact Dennis Fitzgerald at [email protected]